|
|
Expression and clinical significance of miR-1915-3p and Bcl-2 in colon cancer tissues |
YAO Xiaohui |
Department of Pathology, the Second Hospital of Chaoyang City, Liaoning Province, Chaoyang 122000, China |
|
|
Abstract Objective To study the expression and clinical significance of miR-1915-3p and Bcl-2 in colon cancer tissues. Methods A total of 85 colon cancer patients admitted to the Second Hospital of Chaoyang City, Liaoning Province from February 2013 to February 2016 were selected as the research subjects. The cancer tissues and normal adjacent tissues of all patients were collected, and the mRNA expression levels of miR-1915-3p and Bcl-2 in different colon tissues were detected and compared by RT-qPCR. The expression levels of miR-1915-3p and Bcl-2 mRNA in different clinicopathological features and prognosis of colon cancer patients were analyzed. Results The expression level of miR-1915-3p mRNA in colon cancer tissues was lower than that in normal adjacent tissues, while the expression level of Bcl-2 mRNA was higher than that in normal adjacent tissues, the differences were statistically significant (P<0.05). The miR-1915-3p mRNA expression level of colorectal cancer patients with TNM stage Ⅲ-Ⅳ, low differentiation and lymph node metastasis were lower than those of colorectal cancer patients with TNM stage Ⅰ-Ⅱ, medium and high differentiation and no lymph node metastasis, the expression level of Bcl-2 mRNA were higher than those of patients with stage Ⅰ-Ⅱ, medium and high differentiation and no lymph node metastasis, the differences were statistically significant (P<0.05). The expression level of miR-1915-3p mRNA in patients with colon cancer death was lower than that in patients with survival, and the expression level of Bcl-2 mRNA was higher than that in patients with survival, the differences were statistically significant (P<0.05). Conclusion MiR-1915-3p is low expression in colon cancer tissues, while Bcl-2 is high expression in colon cancer tissues, and the expression levels of miR-1915-3p and Bcl-2 are different in patients with different TNM stages, degrees of differentiation, lymph node metastasis and prognosis.
|
|
|
|
|
|
|
|